IGHV Unmutated Status Influences Outcome More Than IGHV1-69 Gene Usage Per Se in Patients With Chronic Lymphocytic Leukemia

Clinical Lymphoma and Myeloma Pub Date : 2009-10-01 DOI:10.3816/CLM.2009.n.076

Ester M. Orlandi, Silvia Zibellini, Cristiana Pascutto, Cristina Picone, Ilaria Giardini, Lara Pochintesta, Mario Lazzarino

{"title":"IGHV Unmutated Status Influences Outcome More Than IGHV1-69 Gene Usage Per Se in Patients With Chronic Lymphocytic Leukemia","authors":"Ester M. Orlandi, Silvia Zibellini, Cristiana Pascutto, Cristina Picone, Ilaria Giardini, Lara Pochintesta, Mario Lazzarino","doi":"10.3816/CLM.2009.n.076","DOIUrl":null,"url":null,"abstract":"In this study, IGHV1-69 gene usage was detected in 46 out of 379 cases (12%) of chronic lymphocytic leukemia (CLL). In comparison with patients using alternative immunoglobulin heavy-chain variable (IGHV) genes, patients with IgHV1-69 CLLs more often presented at advanced stage, lacked somatic hypermutation (unmutated cases, 87% vs. 35%; P = .00001), and expressed unfavorable biologic characteristics. In 12 patients (26%), common amino acid motifs within the heavy-chain third complementarity-determining region were identified, allowing assignment to previously reported stereotyped subsets. In our study, treatment-free survival of patients with unmutated IGVH1-69 did not differ significantly from that of patients expressing unmutated alternative IGHV genes. As such, IGHV1-69 gene usage per se did not seem to be predictive of progressive disease, progression being primarily related to the unmutated IGHV profile.","PeriodicalId":100272,"journal":{"name":"Clinical Lymphoma and Myeloma","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2009-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.3816/CLM.2009.n.076","citationCount":"4","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Lymphoma and Myeloma","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1557919011700245","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 4

Abstract

In this study, IGHV1-69 gene usage was detected in 46 out of 379 cases (12%) of chronic lymphocytic leukemia (CLL). In comparison with patients using alternative immunoglobulin heavy-chain variable (IGHV) genes, patients with IgHV1-69 CLLs more often presented at advanced stage, lacked somatic hypermutation (unmutated cases, 87% vs. 35%; P = .00001), and expressed unfavorable biologic characteristics. In 12 patients (26%), common amino acid motifs within the heavy-chain third complementarity-determining region were identified, allowing assignment to previously reported stereotyped subsets. In our study, treatment-free survival of patients with unmutated IGVH1-69 did not differ significantly from that of patients expressing unmutated alternative IGHV genes. As such, IGHV1-69 gene usage per se did not seem to be predictive of progressive disease, progression being primarily related to the unmutated IGHV profile.

查看原文本刊更多论文

IGHV未突变状态对慢性淋巴细胞白血病患者预后的影响大于IGHV1-69基因本身的使用

在这项研究中，379例慢性淋巴细胞白血病(CLL)患者中有46例(12%)检测到IGHV1-69基因的使用。与使用其他免疫球蛋白重链变量(IGHV)基因的患者相比，IgHV1-69 cll患者更常出现在晚期，缺乏体细胞超突变(未突变病例，87%对35%;P = 0.00001)，并表现出不利的生物学特性。在12名患者(26%)中，在重链第三互补决定区域内发现了共同的氨基酸基序，允许分配到先前报道的刻板亚群。在我们的研究中，未突变的IGVH1-69患者的无治疗生存率与表达未突变的替代IGHV基因的患者无显著差异。因此，IGHV1-69基因的使用本身似乎并不能预测疾病的进展，进展主要与未突变的IGHV谱有关。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Clinical Lymphoma and Myeloma

自引率

0.00%

发文量